The SGLT2 inhibitor which we will study in this protocol, decreases the renal threshold for glucose excretion (occurring on average > 70-90mg/dL in the presence of canagliflozin) and increases glucosuria to approximately 80-100 grams/day, thereby reducing plasma glucose. At the highest FDA approved dose of canagliflozin (300mg/day) given as monotherapy, HbA1c improves by 1.2%. In addition, canagliflozin therapy leads to several other pharmacological effects: evidence of 2-3% weight loss, decreases in systolic blood pressure by about 4.5mmHg from baseline, and an increase in insulin sensitivity all of which contribute to a beneficial clinical profile for patients with T2DM.